Autifony Therapeutics

Autifony Therapeutics is a private, clinical-stage biotech founded in 2011 as a spin-out from GlaxoSmithKline. The company's core expertise lies in translating ion channel biology into therapeutics, with two clinical-stage Kv3 modulators for Fragile X syndrome (AUT00206, with FDA Orphan Drug Designation) and rare myoclonic epilepsies (AUT00201). Beyond these lead rare disease programs, Autifony has built a broader preclinical and early-stage pipeline targeting other CNS disorders, positioning it as a specialist in neuronal excitability and hearing disorders.

Ion channel drug discovery platform specializing in the modulation of the Kv3 family of potassium channels and other novel ion channel targets to regulate neuronal excitability and treat CNS disorders.

Autifony is a first-mover in clinically developing Kv3 modulators, creating a unique niche. It faces indirect competition from other companies targeting neuronal hyperexcitability in epilepsy and Fragile X with different mechanisms (e.g., mGluR5 antagonists, GABA modulators). In broader indications like schizophrenia and hearing loss, it would compete with large pharma and biotechs in highly crowded and challenging fields.